Abstract
Multiple myeloma (MM) is a B cell malignancy characterized by the slow proliferation, primarily in the bone marrow, of a clone of malignant plasma cells that destroy the bone tissue. This disease is lethal in any case and little therapeutic progress has been achieved these last 20 years. Although myeloma cells poorly proliferate in vivo, the in vivo labelling index of the myeloma cells (LI = percentage of myeloma cells in the S-phase) constitutes one of the best prognostic factors (Durie 1980). This emphasizes clearly the importance of knowing the cytokines that control tumoral growth for further improving the therapeutic control of this disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Asaoku H, Kawano M, Iwato K, Tanbe O, Hirano T, Kishimoto T, Kuramoto A (1988) Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood 72:429–432.
Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 84:2008–2011.
Bergui L, Schena M, Gaidano G, Riva M, Caligaris-Cappio F (1989) Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613–618.
Cozzolino F, Torcia M, Aldinucci D, Rubatelli A, Miliani A, Shaw AR, Landsdorp P, Di Gugliemo R (1989) Production of interleukin 1 by bone marrow myeloma cells. Blood 74:380–387.
Durie BGM, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55:364–372.
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem. J. 265:621–636.
Kawano M, Hirano T, Matsuda T, Taga T, Iwato K, Asaoku H, Tang B, Tanabe O,, Tanka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83–85.
Kawano M, Yamamoto I, Iwato K, Tanaka H, Asaoku H, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A (1989) Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646–1649.
Jourdan M, Zhang XG, Portier M, Bataille R, Klein B (1990a) Selection of autocrine IL-6-producing myeloma cell subclones by interferon-alpha in vitro. French Society of Immunology, Abstr., September 27–28, 1990.
Jourdan M, Bataille R, seguin J, Zhang XG, Chaptal PA, Klein B (1990b) Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arth. and Rheum 33:398–403.
Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyck, Bataille R (1989a) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517–526.
Klein B, zhang XG, Jourdan M, Duperray C, portier M, Cantaloube JF, Haagen I, Bataille R (1989b) An IL-6 dependent human myeloma cell line: crucial role of hematopoietic growth factors in its rapid generation. Blood 74(suppl 1):749
Klein B, Zhang XG, Jourdan M, Bataille R (1989c) GM-CSF synergizes with IL-6 in supporting the proliferation of human myeloma cells. Blood 74(suppl 1): 898
Mandelli F, Avvisati G, Petrucci MT (1989) Interferon: a new strategy in the treatment of multiple myeloma. Eur J Haematol suppl 51, 43:129–134.
Novick D, Engelmann H, Wallach D, Rubinstein M (1989) Soluble cytokine receptors are present in normal human urine. J Exp med 170:1409–1414.
Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. 86:7547–7551.
Tohyama N, Karasuyama H, Tada T (1990) Growth autonomy and tumorigenicity of interleukin-6-dependent B cells transfected with interleukin 6 cDNA. J Exp med 171:389–400.
Zhang XG, Klein B, Bataille R (1989) Interleukin-6 is a potent myeloma-cell growth factor in patients with agressive multiple myeloma. Blood 74:11–13.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Klein, B., Zhang, X.G., Jourdan, M., Portier, M., Bataille, R. (1990). Interleukin-6 is a Major Myeloma Cell Growth Factor In Vitro and In Vivo Especially in Patients with Terminal Disease. In: Potter, M., Melchers, F. (eds) Mechanisms in B-Cell Neoplasia 1990. Current Topics in Microbiology and Immunology, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75889-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-75889-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75891-1
Online ISBN: 978-3-642-75889-8
eBook Packages: Springer Book Archive